![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Sputnik V Researchers Confirm Vaccine’s 91.4 Percent Effectiveness
Sputnik V Researchers Confirm Vaccine’s 91.4 Percent Effectiveness
December 15, 2020
Russia’s Sputnik V COVID-19 vaccine has shown 91.4 percent efficacy based on new data from an ongoing phase 3 trial.
Out of 78 confirmed infections among the 22,714 participants, 62 were in individuals who received a placebo, according to the Gamaleya Research Institute. No severe COVID-19 infections were found in participants who received the vaccine, while 20 severe cases were reported in the placebo group.
AstraZeneca announced last week it will launch a study evaluating a double-dose regimen of its COVID-19 candidate AZD1222 in combination with Sputnik V, which uses the same adenovirus-based technology.
Upcoming Events
-
21Oct